322 related articles for article (PubMed ID: 27567685)
1. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
2. Ca
Yu Z; Dou F; Wang Y; Hou L; Chen H
J Neuroinflammation; 2018 Nov; 15(1):316. PubMed ID: 30442153
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.
Yu Z; Yu P; Chen H; Geller HM
J Neurochem; 2014 Jul; 130(1):41-49. PubMed ID: 24606313
[TBL] [Abstract][Full Text] [Related]
4. The Potassium Channel KCa3.1 Represents a Valid Pharmacological Target for Astrogliosis-Induced Neuronal Impairment in a Mouse Model of Alzheimer's Disease.
Wei T; Yi M; Gu W; Hou L; Lu Q; Yu Z; Chen H
Front Pharmacol; 2016; 7():528. PubMed ID: 28105015
[TBL] [Abstract][Full Text] [Related]
5. The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke.
Yi M; Wei T; Wang Y; Lu Q; Chen G; Gao X; Geller HM; Chen H; Yu Z
J Neuroinflammation; 2017 Oct; 14(1):203. PubMed ID: 29037241
[TBL] [Abstract][Full Text] [Related]
6. Activation of the KCa3.1 channel contributes to traumatic scratch injury-induced reactive astrogliosis through the JNK/c-Jun signaling pathway.
Yi M; Dou F; Lu Q; Yu Z; Chen H
Neurosci Lett; 2016 Jun; 624():62-71. PubMed ID: 27163196
[TBL] [Abstract][Full Text] [Related]
7. KCa3.1 deficiency attenuates neuroinflammation by regulating an astrocyte phenotype switch involving the PI3K/AKT/GSK3β pathway.
Wei T; Wang Y; Xu W; Liu Y; Chen H; Yu Z
Neurobiol Dis; 2019 Dec; 132():104588. PubMed ID: 31470105
[TBL] [Abstract][Full Text] [Related]
8. Blockade of KCa3.1 potassium channels protects against cisplatin-induced acute kidney injury.
Chen CL; Liao JW; Hu OY; Pao LH
Arch Toxicol; 2016 Sep; 90(9):2249-2260. PubMed ID: 26438401
[TBL] [Abstract][Full Text] [Related]
9. KCa3.1 Inhibition Switches the Astrocyte Phenotype during Astrogliosis Associated with Ischemic Stroke Via Endoplasmic Reticulum Stress and MAPK Signaling Pathways.
Yu Z; Yi M; Wei T; Gao X; Chen H
Front Cell Neurosci; 2017; 11():319. PubMed ID: 29075181
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34.
Freise C; Querfeld U
Pharmacol Res; 2014 Jul; 85():6-14. PubMed ID: 24813858
[TBL] [Abstract][Full Text] [Related]
11. The difference in gliosis induced by β-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains.
Lü L; Mak YT; Fang M; Yew DT
Biogerontology; 2009 Dec; 10(6):695-710. PubMed ID: 19221889
[TBL] [Abstract][Full Text] [Related]
12. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo.
D'Alessandro G; Catalano M; Sciaccaluga M; Chece G; Cipriani R; Rosito M; Grimaldi A; Lauro C; Cantore G; Santoro A; Fioretti B; Franciolini F; Wulff H; Limatola C
Cell Death Dis; 2013 Aug; 4(8):e773. PubMed ID: 23949222
[TBL] [Abstract][Full Text] [Related]
13. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
14. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
15. The neuroprotective N-terminal amyloid-β core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models.
Lantz MJ; Roberts AM; Delgado DD; Nichols RA
J Neuroinflammation; 2023 May; 20(1):129. PubMed ID: 37245024
[TBL] [Abstract][Full Text] [Related]
16. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
17. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke.
Chen YJ; Nguyen HM; Maezawa I; Grössinger EM; Garing AL; Köhler R; Jin LW; Wulff H
J Cereb Blood Flow Metab; 2016 Dec; 36(12):2146-2161. PubMed ID: 26661208
[TBL] [Abstract][Full Text] [Related]
18. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling.
Zheng JY; Sun J; Ji CM; Shen L; Chen ZJ; Xie P; Sun YZ; Yu RT
Neurobiol Aging; 2017 Jun; 54():112-132. PubMed ID: 28366226
[TBL] [Abstract][Full Text] [Related]
19. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models.
Ongerth T; Russmann V; Fischborn S; Boes K; Siegl C; Potschka H
Eur J Pharmacol; 2014 Oct; 740():72-80. PubMed ID: 25016931
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Ca²⁺-dependent K⁺ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury.
Bouhy D; Ghasemlou N; Lively S; Redensek A; Rathore KI; Schlichter LC; David S
J Neurosci; 2011 Nov; 31(45):16298-308. PubMed ID: 22072681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
